Immunotherapy biomarkers: friends or foes?
Immunotherapy is changing the cancer care paradigm: for a small but significant group of patients, cancer has become a chronic disease and immunotherapy biomarkers like PD-L1 play an important role. In this presentation, Professor Kerr will provide a summary of the immunotherapy treatment landscape, address what makes immunotherapy biomarkers unique compared to biomarkers like HER-2 and ALK, describe the function (physiologic and as a biomarker) of PD-L1 and other biomarkers relevant to the PD-1/PD-L1 pathway. He will also address the role of emerging immunotherapy biomarkers that are independent of the PD-1/PD-L1 pathway.
Recorded
Jun 28 2017
60 mins
Your place is confirmed,
we'll send you email reminders
we'll send you email reminders
Presented by
Professor Keith Kerr, MB, ChB, FRCPath, FRCPE, Consultant Pathologist, Department of Pathology, University of Aberdeen, Aberd
Professor Keith Kerr, MB, ChB, FRCPath, FRCPE, Consultant Pathologist, Department of Pathology, University of Aberdeen, Aberd
Presentation preview:
Network with like-minded attendees
-
![[[ session.user.profile.displayName ]]](data:image/gif;base64,R0lGODlhAQABAIAAAP7//wAAACH5BAAAAAAALAAAAAABAAEAAAICRAEAOw==)
- [[ session.user.profile.displayName ]]
- [[ session.user.profile.jobTitle ]]
- [[ session.user.profile.companyName ]]
- [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
-
- [[ card.displayName ]]
- [[ card.jobTitle ]]
- [[ card.companyName ]]
- [[ userProfileTemplateHelper.getLocation(card) ]]
- Channel
- Channel profile
-
Panel Discussion-Prioritizing Testing in the Context of Predictive Markers Recorded: May 1 2019 9 mins
Panel DiscussionPanel Discussion-Prioritizing Testing in the Context of Predictive Markers hosted by Dr. Paul A. Bunn Jr, MD. Panel participants include Dr. Philippe Taniere, MD, PhD, Dr. Erik Thunnissen, FBJM, and Dr Emd (Ed) Schuuring, Prof Dr. -
Panel Discussion-Making Appropriate Diagnosis in Lung Cancer Recorded: May 1 2019 28 mins
Panel DiscussionPanel Discussion-Making Appropriate Diagnosis in Lung Cancer with Dr. Paul A. Bunn Jr, MD,as your host. The panel includes Dr. Corrado D'Arrigo, MBChB, PhD, FRCPath, Dr. Mark Kockx, MD, PhD, and Dr. Erik Thunnissen, FBJM. -
Panel Discussion-Collaboration & Partnership between Oncologists & Pathologist Recorded: May 1 2019 21 mins
Panel DiscussionPanel Discussion-Collaboration and Partnership between Oncologists and Pathologists with Dr. Paul A. Bunn, MD, as your host. Panel participants include Prof Dr. EMD (Ed) Schuuring, Prof Dr. HJM (Harry) Groen, and Dr. Corrado D'Arrigo, MBChB, PhD, FRCPath -
The Dangers of Using a Laboratory-Developed Test as a Companion Diagnostic Recorded: May 1 2019 25 mins
Keith Miller, FIBMSThe Dangers of Using a Laboratory-Developed Test as a Companion Diagnostic presented by Keith Miller, FIBMS, Director, UK National External Quality Assessment Scheme for Immunohistochemistry and in Situ Hybridization -
Lung Cancer Biomarker Testing Recorded: Apr 29 2019 20 mins
Dr. Paul A. Bunn Jr, MDLung Cancer Biomarker Testing presented by Dr. Paul A. Bunn Jr, MD, Distinguished Professor and Dudley Endowed Chair University of Colorado Cancer Center, Aurora, CO, USA -
ALK IHC vs ISH and ALK Inhibitors in Treatment of ALK-Positive Advanced NSCLC Recorded: Apr 29 2019 32 mins
Prof Dr EMD (Ed) Schuuring and Prof Dr HJM (Harry) GroenALK IHC vs ISH and ALK Inhibitors in Treatment of ALK-Positive Advanced NSCLC presented by Prof Dr. EMD (Ed) Schuuring, Clinical Scientist in Molecular Pathology, University Medical Center Groningen The Netherlands and Prof Dr. HJM (Harry) Groen, Pulmonologist, University Medical Center Groningen The Netherlands. -
ROS1 in NSCLC Pathology and Prediction Recorded: Apr 29 2019 12 mins
Dr. Erik Thunnissen, FBJMROS1 in NSCLC Pathology and Prediction presented by Dr. Erik Thunnissen, FBJM, Department of Pathology, VU University Medical Center Amsterdam, The Netherlands -
Small Cell Lung Cancer Recorded: Apr 29 2019 30 mins
Dr. Erik Thunnissen, FBJMSmall Cell Lung Cancer presented by Dr. Erik Thunnissen, FBJM, Department of Pathology, VU University Medical Center Amsterdam, the Netherlands. -
EGFR Mutation in Lung Carcinoma Recorded: Apr 29 2019 11 mins
Dr. Philippe Taniere, MD, PhDEGFR Mutation in Lung Carcinoma presented by Dr. Philippe Taniere, MD, PhD, Consultant Pathologist at University Hospital Birmingham, Birmingham, UK -
Somewhere over the Rainbow: Applications of brightfield IHC Multiplexing Recorded: Apr 29 2019 49 mins
Gregory L. Beatty, MD, PhD and Nate Polaske, PhDLearn more about applications of IHC multiplexing with next-generation chromogenic staining on DISCOVERY ULTRA system -
Diagnostic Assessment of Lung Cancer for the Pathologist Recorded: Apr 26 2019 16 mins
Dr. Corrado D'Arrigo, MDDiagnostic Assessment of Lung Cancer for the Pathologist presented by Dr. Corrado D'Arrigo, MD, Consultant Pathologist and Founder Poundbury Cancer Institute, Poundbury, UK -
Fundamentals of Lung Cancer Testing Recorded: Apr 26 2019 3 mins
Dr. Paul A. Bunn, MDFundamentals of Lung Cancer Testing presented by Dr. Paul A. Bunn Jr, MD, Distinguished Professor and Dudley Endowed Chair University of Colorado Cancer Center, Aurora, CO, USA -
Battle of the ALKs: ALK IHC vs. ISH in treatment of ALK-positive advanced NSCLC Recorded: Feb 28 2019 56 mins
Prof Dr EMD (Ed) Schuuring & Prof Dr HJM (Harry) GroenJoin Dr. Ed Schuuring and Dr. Harry Groen, University Medical Center Groningen, The Netherlands, to explore the role of immunohistochemistry (IHC) in the assessment of ALK rearrangements in non-small cell lung cancer (NSCLC), with a focus on the binary algorithm and comparison with fluorescence in situ hybridization (FISH). Clinical implications for ALK IHC vs. FISH and treatment options for ALK inhibitors will be discussed including side effects and overall as well as intracranial efficacy. -
PD-L1 Assays – More than just an antibody Recorded: Sep 18 2018 33 mins
Dr. Michael FloresIn this webinar, Dr. Flores will summarize the PD-L1 testing assays currently available on market and address the importance of understanding the different scoring algorithms developed for their respective PD-1/PD-L1 immunotherapies. You will learn about a system approach to testing and where to find further information on how to appropriately interpret the specific PD-L1 assay you are working with. -
Multiplexed immunofluorescence and digital image analysis for clinical use Recorded: Jun 28 2018 63 mins
Mehrnoush Khojasteh, PhD & Lei Tang, PhDThere is an ever increasing need to understand the role of the Tumor Microenvironment (TME) in Cancer Immunotherapy. In this webinar, Drs. Lei Tang, PhD and Mehrnoush Khojasteh,PhD of Roche Tissue Diagnostics (Ventana Medical Systems, Inc.), present their work on multiplex immunofluorescence staining and digital pathology analysis in a CAP/CLIA certified laboratory. Multiplexed immunohistochemistry (IHC) enables the spatial characterization of TME immune cells and tumor cells by detecting multiple biomarkers while preserving tissue morphology. Co-expression of multiple biomarkers and relative spatial relationships requires whole slide digital pathology image analysis algorithms that are tailored to individual assays and their intended uses. The process described in this presentation demonstrates how multiplexing and digital pathology enable biotech and pharmaceutical research and development teams to explore the potential medical value of specific biomarkers, -
Immunotherapy biomarkers: friends or foes? Recorded: Jun 28 2017 60 mins
Professor Keith Kerr, MB, ChB, FRCPath, FRCPE, Consultant Pathologist, Department of Pathology, University of Aberdeen, AberdImmunotherapy is changing the cancer care paradigm: for a small but significant group of patients, cancer has become a chronic disease and immunotherapy biomarkers like PD-L1 play an important role. In this presentation, Professor Kerr will provide a summary of the immunotherapy treatment landscape, address what makes immunotherapy biomarkers unique compared to biomarkers like HER-2 and ALK, describe the function (physiologic and as a biomarker) of PD-L1 and other biomarkers relevant to the PD-1/PD-L1 pathway. He will also address the role of emerging immunotherapy biomarkers that are independent of the PD-1/PD-L1 pathway. -
From biopsy to treatment: A tissue journey through pathology Recorded: May 12 2017 43 mins
Zin Htway, PhD, MBAHM, CT (ASCP, IAC), Maria Magana, Danielle Westfall, MD, Los Robles Hospital and Medical CenterSurgical procurement of adequate tissue can be challenging. This presentation will be an in-depth look at rapid on-site evaluation of tissue biopsies from various sites. Best practices for handling, grossing and histology sectioning of tissue biopsies for companion diagnostics will be discussed. This will be followed by a brief overview of this approach applied to immunohistochemistry stains and fluorescence in situ hybridization. -
Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers Recorded: Mar 29 2017 58 mins
Yaso Natkunam, MD, PhD, Professor of Pathology, Director of Hematopathology, Stanford University School of MedicineJoin us for the March CDx Insights webinar “Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers.” Our speaker is Yaso Natkunam, MD, PhD, Professor of Pathology and Director of Hematopathology at Stanford University School of Medicine. Dr Natkunam will review key updates to the classifications of large B-cell lymphomas in the “2016 revision of the World Health Organization classification of lymphoid neoplasms.” She will also discuss the role of diagnostic and predictive biomarkers in DLBCL, high grade B-cell lymphoma and other large B-cell lymphomas. -
Part 2: Tumor heterogeneity and immuno-oncology Recorded: Mar 15 2017 2 mins
Tom Grogan, MD, Founder, Senior Vice President, Ventana Medical Systems Inc.View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD, Founder and Senior Vice President of Scientific Affairs of Ventana Medical Systems, Inc. Dr. Grogan addresses the role of IHC in companion diagnostics, assessment of heterogeneity and the interplay between the immune system and cancer. -
Part 1: CDx, IHC and tumor heterogeneity Recorded: Mar 15 2017 4 mins
Tom Grogan, MD,Senior Vice President, Founder, Ventana Medical Systems Inc.View two new CDx Insights videos “Part 1: CDx, IHC and tumor heterogeneity” and “Part 2: Tumor heterogeneity and immuno-oncology” with Tom Grogan, MD, Founder and Senior Vice President of Scientific Affairs of Ventana Medical Systems, Inc. Dr. Grogan addresses the role of IHC in companion diagnostics, assessment of heterogeneity and the interplay between the immune system and cancer.
CDx Insights
CDx Insights is a series brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
![[[ webcast.title ]]](/resources/images/diamond-100x75.jpg?v=4e0d5a8249946c989a1d5df52f35eb4a455dd831)
Successfully added emails: 0
Remove all
- Title: Immunotherapy biomarkers: friends or foes?
- Live at: Jun 28 2017 4:00 pm
- Presented by: Professor Keith Kerr, MB, ChB, FRCPath, FRCPE, Consultant Pathologist, Department of Pathology, University of Aberdeen, Aberd
- From: